Ariana Pelosci

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Data from the NATALEE trial show that ribociclib may benefit a broad population of patients with early breast cancer who have an increased risk of recurrent disease.

Results from the phase 3 KarMMa-3 trial of ide-cel vs standard of care in previously treated multiple myeloma led to the FDA approval.

Utidelone injection may cross the blood-brain barrier and help treat patients with breast cancer brain metastases.

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

A Miami Breast Cancer Conference presentation focused on how the new ASTRO partial breast irradiation guidelines could be incorporated into practice.

Rian M. Hasson Charles, MD, MPH, FACS, has a first-of-its-kind role at Brigham and Women’s Hospital that will focus on health equity.

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

The phase 3 KEYLYNK-006 trial did not meet the primary end points of progression-free and overall survival in patients with metastatic nonsquamous non–small cell lung cancer.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

Results from the KEYNOTE-868 trial showed a favorable benefit of pembrolizumab plus chemotherapy across endometrial cancer subgroups.

The ODAC meeting concluded that ide-cel showed a favorable risk/benefit profile for patients with pretreated relapsed/refractory multiple myeloma.

ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.

A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.

Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.

The use of a robot to aid in nipple-sparing surgery has been a controversial topic, although ongoing trials may show its potential.

Data from the phase 3 VIALE-A trial showed continued responses during long-term follow-up for patients with newly diagnosed acute myeloid leukemia treated with venetoclax/azacitidine.

Patients with relapsed/refractory follicular lymphoma can now receive zanubrutinib plus obinutuzumab based on the data from the phase 2 ROSEWOOD trial.

Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.

Denosumab biosimilars have been approved by the FDA as Wyost and Jubbonti across various reference indications.

A prospective phase 2 trial evaluated the use of de-escalation therapy for patients with p16-positive squamous cell carcinoma.

Results from cohort A of a pilot study of patients with HPV–associated oropharyngeal carcinoma did not meet its primary end point.

A post hoc analysis of lurbinectedin showed an improvement in the overall response rate compared with topotecan for patients with small cell lung cancer.

Authors of a study from the American Cancer Society estimate over 2 million new cancer cases in 2024.

A phase 1/2 study found that using azacitidine, venetoclax, and gilteritinib for patients with FLT3-mutated acute myeloid leukemia yielded high rates of complete response and complete response with incomplete hematologic recovery.

A phase 2 trial found that ruxolitinib cream significantly improved body surface area compared with vehicle cream in patients with cutaneous graft-vs-host disease.